Similar mean improvements seen in total, storage, voiding, QoL scores for severe, nonsevere LUTS cohorts

WEDNESDAY, May 8, 2024 (HealthDay News) -- For patients with severe low urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO), Silodosin improves symptoms and quality of life (QoL), according to a study published in the March 2021 issue of European Urology Focus.

Massimiliano Creta, Ph.D., from the University of Naples Federico II in Italy, and colleagues performed a post-hoc analysis of data from phase 3 and 4 studies to assess the efficacy of Silodosin 8 mg in patients with severe LUTS related to BPO. Severity was defined according to the presence of two or more of the following: total International Prostate Symptom Score (IPSS) 20 to 35, QoL score 5 to 6, maximum urinary flow.

The researchers found that compared with patients receiving placebo, those receiving Silodosin had significantly greater mean improvements in total (8.1 versus 4.7), storage (3.1 versus 2.0), voiding (5.0 versus 2.7), and QoL (1.3 versus 0.7) IPSS scores. Severe and nonsevere LUTS cohorts had similar mean improvements in total, storage, voiding, and QoL IPSS scores.

"Silodosin 8 mg once daily provides significant symptomatic benefits in all patients with LUTS/BPO, including those with severe LUTS. It is thus a valid strategy in the absence of a mandatory indication for surgery for patients who want to delay or are waiting for surgery,"

Abstract/Full Text (subscription or payment may be required)